共 50 条
- [2] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study [J]. Dermatology and Therapy, 2024, 14 : 213 - 232
- [4] Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study [J]. Dermatology and Therapy, 2023, 13 : 1817 - 1830
- [6] Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study [J]. Rheumatology and Therapy, 2023, 10 : 275 - 292
- [9] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up) [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
- [10] A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up) An interim 24-week analysis [J]. JAAD INTERNATIONAL, 2022, 6 : 27 - 36